Aromatase Inhibitor News and Research

RSS

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.

10-year results from clinical trial of extended letrozole therapy for women with HR+ breast cancer

In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.

12 Dec 2019

Tart cherry reduces joint pain and sore muscles in some breast cancer patients, study shows

Tart cherry reduces the musculoskeletal effects of aromatase inhibitors in patients with non-metastatic breast cancer, according to new findings from a clinical trial by researchers at Marshall University Joan C. Edwards School of Medicine and Edwards Comprehensive Cancer Center.

10 Jun 2019

Targeted breast cancer therapy shows 'encouraging' results

Researchers have developed a targeted therapy that may significantly increase the survival of pre-menopausal women with advanced breast cancer

3 Jun 2019

Targeted therapy plus hormone therapy improves survival in premenopausal patients with advanced HR+ breast cancer

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2019

FRAX tool useful in breast cancer patients treated with aromatase inhibitors

The FRAX® tool takes into account certain factors to determine the risk of bone fracture in the general population.

9 May 2019

FDA extends indication of metastatic breast cancer treatment to include male patients

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

5 Apr 2019

Altering gut microbiome may be potential treatment option for PCOS

Symptoms of polycystic ovary syndrome improved with exposure to healthy bacteria in the gut, according to a study in a mouse model of this common women's endocrine disorder.

25 Mar 2019

Neuron-derived estrogen key to making memories

Estrogen in the brain is important to keep neurons communicating and memories being made, scientists report.

25 Feb 2019

Genetic changes may predict likelihood of relapse in breast cancer patients

Scientists have identified genetic changes that may predict the likelihood of breast cancer relapse in women taking a common type of hormone therapy.

22 Jan 2019

Study: Drug reduces hot flash frequency, improves quality of life in breast cancer survivors

Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors.

7 Dec 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.

22 Oct 2018

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Age-related estrogen increase may be the culprit behind inguinal hernias in men

An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 in Proceedings of the National Academy of Sciences.

16 Oct 2018

FDA grants approval for first breast cancer drug through 'Real-Time Oncology Review'

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

19 Jul 2018

Study finds combination therapy to be safe, effective for treatment of male infertility

Two drugs that are commonly used off-label in the treatment of male infertility are clomiphene citrate (CC) and anastrozole (AZ); however, data are lacking on the use of combination CC+AZ therapy.

6 Jun 2018

QMUL professor receives Cancer Research UK Lifetime Achievement Award

Professor Jack Cuzick from Queen Mary University of London has received the Cancer Research UK Lifetime Achievement Award for his work on cancer prevention and detection.

19 Sep 2017

Astex celebrates as breast cancer drug gets European marketing approval

Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received marketing approval in Europe for Kisqali (ribociclib) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.

26 Aug 2017

Aspirin used in “baby” doses may prevent breast cancer, study suggests

A new study led by City of Hope researchers has found that regular use of low-dose aspirin (81mg) reduces breast cancer risk in women. Led by Leslie Bernstein, the team found that women who took the low-dose aspirin, also known as “baby” aspirin, at least three times per week had an overall 16% reduced risk of developing breast cancer.

2 May 2017

Researchers find link between hormones and inguinal hernias in older men

Researchers have identified an apparent cause of inguinal hernia, or groin hernia, in older men: altered sex hormone levels that weaken and scar muscle tissue in the lower abdomen.

3 Apr 2017